| Recruiting | STOP-PKD: SGLT2-inhibition to Improve Prognosis in Polycystic Kidney Disease NCT07280585 | University of Cologne | Phase 3 |
| Active Not Recruiting | Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease NCT05510115 | University of Colorado, Denver | Phase 2 |
| Completed | A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease NCT05521191 | Regulus Therapeutics Inc. | Phase 1 |
| Completed | Time Restricted Feeding in Autosomal Dominant Polycystic Kidney Disease NCT04534985 | University of Colorado, Denver | N/A |
| Completed | PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD (PENGUIN) NCT04407481 | University of Colorado, Denver | — |
| Unknown | Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt NCT04310319 | Esther Meijer | N/A |
| Completed | Effect of Venglustat in Patients With Renal Impairment NCT03687554 | Genzyme, a Sanofi Company | Phase 1 |
| Terminated | A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients NCT03523728 | Genzyme, a Sanofi Company | Phase 2 / Phase 3 |
| Completed | Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Poly NCT03342742 | University of Colorado, Denver | N/A |
| Completed | The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney Dise NCT04363554 | Regional Hospital Holstebro | N/A |
| Completed | Feasibility Study of Metformin Therapy in ADPKD NCT02903511 | University of Colorado, Denver | Phase 2 |
| Completed | Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease NCT02656017 | Kyongtae Ty Bae, M.D., Ph.D. | Phase 2 |
| Completed | Effect of Tolvaptan on Renal Plasma Flow (RPF) and Glomerular Filtration Rate (GFR) in ADPKD NCT03803124 | Regional Hospital Holstebro | Phase 3 |
| Completed | Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD NCT02494141 | University of Colorado, Denver | Phase 4 |
| Completed | Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease NCT02251275 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 3 |
| Completed | Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD NCT02847624 | Otsuka Pharmaceutical Co., Ltd. | — |
| Completed | Ursodeoxycholic Acid as Treatment for Polycystic Liver Disease NCT02021110 | Radboud University Medical Center | Phase 2 |
| Completed | A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidn NCT01559363 | Kadmon, a Sanofi Company | Phase 1 / Phase 2 |
| Terminated | The Relation Between Uric Acid Level and Endothelial Dysfunction in Patients With Polycystic Kidney Disease NCT01589705 | TC Erciyes University | — |
| Completed | The Role of Endothelial Dysfunction in Adult Polycystic Kidney Disease NCT04023214 | Sheffield Teaching Hospitals NHS Foundation Trust | — |
| Completed | Bosutinib For Autosomal Dominant Polycystic Kidney Disease NCT01233869 | Pfizer | Phase 2 |
| Completed | Pilot Study of RNA as a Biomarker for Autosomal Dominant Polycystic Kidney Disease NCT01114594 | The Rogosin Institute | — |
| Completed | Lanreotide as Treatment of Polycystic Livers NCT00565097 | Radboud University Medical Center | Phase 2 / Phase 3 |
| Completed | Octreotide in Severe Polycystic Liver Disease NCT00426153 | Mayo Clinic | Phase 2 / Phase 3 |
| Completed | Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD) NCT00456365 | University of Colorado, Denver | Phase 3 |
| Completed | The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Autosomal Dominant Polycystic Kidney Diseas NCT00410007 | Carolina Cannillo | N/A |
| Completed | Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Di NCT00413777 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 2 |